PAM
CHRS icon

Panagora Asset Management’s Coherus Oncology CHRS Stock Holding History

Panagora Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.47M Sell
1,459,310
-160,961
-10% -$286K 0.01% 545
2025
Q4 		$2.3M Buy
1,620,271
+244,303
+18% +$356K 0.01% 538
2025
Q3 		$2.26M Buy
1,375,968
+581,639
+73% +$647K 0.01% 501
2025
Q2 		$581K Buy
+794,329
New +$686K ﹤0.01% 763
2022
Q2 		– Sell
-188,094
Closed -$2.43M – 1489
2022
Q1 		$2.43M Buy
188,094
+9,346
+5% +$119K 0.01% 629
2021
Q4 		$2.85M Buy
+178,748
New +$3.13M 0.02% 539
2021
Q3 		– Sell
-110
Closed -$2K – 1836
2021
Q2 		$2K Sell
110
-2,995
-96% -$42.4K ﹤0.01% 2622
2021
Q1 		$45K Hold
3,105
– – ﹤0.01% 2199
2020
Q4 		$54K Hold
3,105
– – ﹤0.01% 2026
2020
Q3 		$57K Hold
3,105
– – ﹤0.01% 1985
2020
Q2 		$55K Sell
3,105
-28,277
-90% -$479K ﹤0.01% 1952
2020
Q1 		$509K Sell
31,382
-209,989
-87% -$3.88M ﹤0.01% 1108
2019
Q4 		$4.35M Buy
241,371
+213,757
+774% +$3.94M 0.02% 527
2019
Q3 		$559K Buy
+27,614
New +$552K ﹤0.01% 1246
2017
Q1 		– Sell
-52,138
Closed -$1.47M – 2385
2016
Q4 		$1.47M Buy
+52,138
New +$1.46M 0.01% 1036
2016
Q1 		– Sell
-827
Closed -$19K – 2298
2015
Q4 		$19K Sell
827
-1,454
-64% -$37.4K ﹤0.01% 2149
2015
Q3 		$46K Buy
2,281
+1,610
+240% +$49K ﹤0.01% 2010
2015
Q2 		$19K Sell
671
-53,010
-99% -$1.34M ﹤0.01% 2313
2015
Q1 		$1.64M Buy
53,681
+24,566
+84% +$635K 0.01% 858
2014
Q4 		$475K Buy
+29,115
New +$411K ﹤0.01% 1304

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Panagora Asset Management's CHRS Position: Q1 2026 in Review

Panagora Asset Management reduced its Coherus Oncology (CHRS) stake by 9.9% in Q1 2026, selling an estimated $286K and leaving 1,459,310 shares worth $2.47M. The position accounts for 0.01% of the portfolio, ranked #545.

Panagora Asset Management first reported a position in CHRS in Q4 2014 and has held it in 20 quarters since. The position peaked at $4.35M in Q4 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Panagora Asset Management held 1,459,310 shares of Coherus Oncology worth $2.47M as of Q1 2026.
  • Panagora Asset Management sold 160,961 Coherus Oncology shares in Q1 2026, an estimated $286K.
  • Coherus Oncology made up 0.01% of Panagora Asset Management's portfolio in Q1 2026, its #545 holding.
  • Panagora Asset Management first reported a position in Coherus Oncology in Q4 2014 and has held it in 20 quarters since.
  • Panagora Asset Management's Coherus Oncology position peaked at $4.35M in Q4 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.